BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016; 8(21): 881-890 [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Guerrini GP, Pinelli D, Marini E, Corno V, Guizzetti M, Zambelli M, Aluffi A, Lincini L, Fagiuoli S, Lucianetti A, Colledan M. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation. Prog Transplant 2018;28:63-9. [PMID: 29251164 DOI: 10.1177/1526924817746686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ren X, Ji Y, Jiang X, Qi X. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Biosci Rep 2018;38:BSR20181423. [PMID: 30355653 DOI: 10.1042/BSR20181423] [Reference Citation Analysis]
3 Huang PS, Lin YH, Chi HC, Tseng YH, Chen CY, Lin TK, Yeh CT, Lin KH. Dysregulated FAM215A Stimulates LAMP2 Expression to Confer Drug-Resistant and Malignant in Human Liver Cancer. Cells 2020;9:E961. [PMID: 32295144 DOI: 10.3390/cells9040961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Li YP, Wang WZ, Chen XQ, Li LB, Liang ZY, Ru K, Li JN. Signal Transducer and Activator of Transcription 3 for the Differentiation of Hepatocellular Carcinoma from Cirrhosis. Chin Med J (Engl) 2017;130:2686-90. [PMID: 29133756 DOI: 10.4103/0366-6999.218016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Gurakar A, Ma M, Garonzik-wang J, Kim A, Anders RA, Oshima K, Georgiades C, Gurakar M, Ottmann S, Cameron AM, Philosophe B, Saberi B. Clinicopathological Distinction of Low-AFP-Secreting vs. High-AFP-Secreting Hepatocellular Carcinomas. Annals of Hepatology 2018;17:1052-66. [DOI: 10.5604/01.3001.0012.7206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wu JL, Su TH, Chen PJ, Chen YR. Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level. Sci Rep 2022;12:5799. [PMID: 35388082 DOI: 10.1038/s41598-022-09713-9] [Reference Citation Analysis]
8 Cao X, Zhang Y, Zhou Q, Sun S, He M, Wang X, Ma P, Yang X, Lv L, Zhan L. Establishment of a Novel Mouse Hepatocellular Carcinoma Model for Dynamic Monitoring of Tumor Development by Bioluminescence Imaging. Front Oncol 2022;12:794101. [DOI: 10.3389/fonc.2022.794101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Muscari F, Maulat C. Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date? Transl Gastroenterol Hepatol 2020;5:46. [PMID: 33073041 DOI: 10.21037/tgh.2019.12.09] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Saberi B, Garonzik-Wang J, Ma M, Ajayi T, Kim A, Luu H, Jakhete N, Pustavoitau A, Anders RA, Georgiades C, Kamel I, Ottmann S, Philosophe B, Cameron AM, Gurakar A. Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma. Exp Clin Transplant 2020;18:463-9. [PMID: 30084757 DOI: 10.6002/ect.2017.0288] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 164] [Article Influence: 30.6] [Reference Citation Analysis]
12 Yu K, Tang J, Wu JL, Li B, Wu SN, Zhang MY, Li QY, Zhang LJ, Pan YC, Ge QM, Shu HY, Shao Y. Risk factors for intraocular metastasis of primary liver cancer in diabetic patients: Alpha-fetoprotein and cancer antigen 125. World J Diabetes 2021; 12(2): 158-169 [PMID: 33594335 DOI: 10.4239/wjd.v12.i2.158] [Reference Citation Analysis]
13 Ivanics T, Rajendran L, Abreu P, Claasen M, Shwaartz C, Patel M, Choi W, Doyle A, Muaddi H, Mcgilvray I, Selzner M, Beecroft R, Kachura J, Bhat M, Selzner N, Ghanekar A, Cattral M, Sayed B, Reichman T, Lilly L, Sapisochin G. Long-term outcomes of ablation, liver resection, and liver transplant as first-line treatment for solitary HCC of 3 cm or less using an intention-to-treat analysis: A retrospective cohort study. Annals of Medicine and Surgery 2022;77:103645. [DOI: 10.1016/j.amsu.2022.103645] [Reference Citation Analysis]
14 Gao S, Gang J, Yu M, Xin G, Tan H. Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer. BMC Cancer 2021;21:791. [PMID: 34238253 DOI: 10.1186/s12885-021-08520-1] [Reference Citation Analysis]
15 Herrero A, Boivineau L, Cassese G, Assenat E, Riviere B, Faure S, Bedoya JU, Panaro F, Guiu B, Navarro F, Pageaux GP. Progression of AFP SCORE is a Preoperative Predictive Factor of Microvascular Invasion in Selected Patients Meeting Liver Transplantation Criteria for Hepatocellular Carcinoma. Transpl Int 2022;35:10412. [PMID: 35401038 DOI: 10.3389/ti.2022.10412] [Reference Citation Analysis]
16 Nörthen A, Asendorf T, Walson PD, Oellerich M. Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. Clinical Biochemistry 2018;52:20-5. [DOI: 10.1016/j.clinbiochem.2017.10.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
17 Xiao S, Hu Z, He Y, Jin H, Yang Y, Chen L, Chen Q, Luo Q, Liu J. Enhancement Effect of Microbubble-Enhanced Ultrasound in Microwave Ablation in Rabbit VX2 Liver Tumors. Biomed Res Int 2020;2020:3050148. [PMID: 32090074 DOI: 10.1155/2020/3050148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lamm R, Altshuler PJ, Patel K, Shaheen O, Amante AP, Civan J, Maley W, Frank A, Ramirez C, Glorioso J, Shah A, Dang H, Bodzin AS. Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis. Transpl Int 2022;35:10175. [DOI: 10.3389/ti.2022.10175] [Reference Citation Analysis]
19 Hogen R, Lo M, Dinorcia J, Ji L, Genyk Y, Sher L, Dhanireddy K. More Than Just Wait Time? Regional Differences in Liver Transplant Outcomes for Hepatocellular Carcinoma. Transplantation 2019;103:747-54. [DOI: 10.1097/tp.0000000000002248] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]